Journal Article

Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial

Terui, Tadashi, Kobayashi, Satomi, Okubo, Yukari, Kikuta, Natsuko, Sano, Shigetoshi, Murakami, Masamoto, Ouchi, Yoshiumi

2024

Overview

Background Palmoplantar pustulosis (PPP), a refractory skin disease characterized by repeated eruptions of sterile pustules and vesicles on palms and/or soles, involves interleukin-17 pathway activation. Brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, is being investigated for use in PPP treatment. Objective The aim was to assess the efficacy and safety of brodalumab in Japanese PPP patients with moderate or severe pustules/vesicles. Methods A phase 3, randomized, double-blind, placebo-controlled trial was conducted between July 2019 and August 2022, at 41 centers in Japan. Patients aged 18–70 years with a diagnosis of PPP for ≥ 24 weeks, a PPP Area Severity Index (PPPASI) score of ≥ 12, a PPPASI subscore of pustules/vesicles of ≥ 2, and inadequate response to therapy were included. Participants were randomized 1:1 to receive brodalumab 210 mg or placebo, subcutaneously (SC) at baseline, weeks 1 and 2, and every 2 weeks (Q2W) thereafter until week 16. Changes from baseline to week 16 in the PPPASI total score (primary endpoint) and other secondary skin-related endpoints and safety endpoints were assessed. Results Of the 126 randomized patients, 50 of 63 in the brodalumab group and 62 of 63 in the placebo group completed the 16-week period. Reasons for discontinuation were adverse event ( n = 6), withdrawal by patient/parent/guardian ( n = 3), progressive disease ( n = 3), and lost to follow-up ( n = 1) in the brodalumab group and Good Clinical Practice deviation ( n = 1) in the placebo group. Change from baseline in the PPPASI total score at week 16 was significantly higher ( p = 0.0049) with brodalumab (least-squares mean [95% confidence interval {CI}] 13.73 [10.91–16.56]) versus placebo (8.45 [5.76–11.13]; difference [95% CI] 5.29 [1.64–8.94]). At week 16, brodalumab showed a trend of rapid improvement versus placebo for PPPASI-50/75/90 response (≥ 50%/75%/90% improvement from baseline) and Physician’s Global Assessment 0/1 score: 54% versus 24.2%, 36.0% versus 8.1%, 16.0% versus 0.0%, and 32.0% versus 9.7%, respectively. Infection was the dominant treatment-emergent adverse event (TEAE); the commonly reported TEAEs were otitis externa (25.4%/1.6%), folliculitis (15.9%/3.2%), nasopharyngitis (14.3%/4.8%), and eczema (14.3%/12.9%) in the brodalumab/placebo groups, respectively. The severity of most TEAEs reported was Grade 1 or 2 and less frequently Grade ≥ 3. Conclusions Brodalumab SC 210 mg Q2W demonstrated efficacy in Japanese PPP patients. The most common TEAEs were mild infectious events. Trial Registration NCT04061252 (Date of Trial Registration: August 19, 2019)

• Publisher: Springer International Publishing,Springer Nature B.V
• Subject: Adolescent / Adult / Aged / Antibiotics / Antibodies, Monoclonal, Humanized - administration & dosage / Antibodies, Monoclonal, Humanized - adverse effects / Consent / Cytokines / Dermatology / Double-Blind Method / Double-blind studies / Female / Humans / Infections / Injections, Subcutaneous / Internet resources / Investigations / Japan / Kinases / Light therapy / Male / Medicine / Medicine & Public Health / Middle Aged / Monoclonal antibodies / NCT / NCT04061252 / Original / Original Research Article / Pharmacology/Toxicology / Pharmacotherapy / Psoriasis / Psoriasis - drug therapy / Psoriasis - immunology / Receptors, Interleukin-17 - antagonists & inhibitors / Receptors, Interleukin-17 - immunology / Severity of Illness Index / Skin diseases / Treatment Outcome / Young Adult